Cargando…

Sustained response following BTK inhibitors based treatment in HIV-related primary central nervous system lymphoma: case report

BACKGROUND: Despite increasing effort for treating primary central nervous system lymphoma (PCNSL), the prognosis of human immunodeficiency virus (HIV) -related PCNSL was still unsatisfactory. There is currently a lack of clinical evidence for the application of Bruton tyrosine kinase (BTK) inhibito...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Ying, Wang, Xiaoxue, Lin, Xuyong, Wang, Jun, Yan, Xiaojing, Wen, Ying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10466696/ https://www.ncbi.nlm.nih.gov/pubmed/37644480 http://dx.doi.org/10.1186/s12981-023-00554-8

Ejemplares similares

The Immunomodulatory Functions of BTK Inhibition in the Central Nervous System
por: Cao, Tingyu, et al.
Publicado: (2022)

BTK inhibitor combined with anti-PD-1 monoclonal antibody for the treatment of CD20-negative primary central nervous system lymphoma: A case report
por: Feng, Lan, et al.
Publicado: (2022)

Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma
por: Jiang, Vivian Changying, et al.
Publicado: (2023)

Genomic Profiling Reveals Differences in Primary Central Nervous System Lymphoma and Large B-Cell Lymphoma, With Subtyping Suggesting Sensitivity to BTK Inhibition
por: Severson, Eric A, et al.
Publicado: (2023)

Primary Central Nervous System Lymphoma
por: Dong, Yan-Hong, et al.
Publicado: (2016)

Case report: CD19-directed CAR-T cell therapy combined with BTK inhibitor and PD-1 antibody against secondary central nervous system lymphoma
por: Zhang, Wenqi, et al.
Publicado: (2022)

P1219: BGB-16673, A BTK DEGRADER, OVERCOMES ON-TARGET RESISTANCE FROM BTK INHIBITORS AND PRESENTS SUSTAINABLE LONG-TERM TUMOR REGRESSION IN LYMPHOMA XENOGRAFT MODELS
por: Wang, Haitao, et al.
Publicado: (2023)

The resistance mechanisms and treatment strategies of BTK inhibitors in B‐cell lymphoma
por: Wang, Haoran, et al.
Publicado: (2021)

Current and emerging therapies for primary central nervous system lymphoma
por: Yuan, Yan, et al.
Publicado: (2021)

Discovery of a Potent, Covalent BTK Inhibitor for B-Cell Lymphoma
por: Wu, Hong, et al.
Publicado: (2014)

Relapsed/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors
por: Burkart, Madelyn, et al.
Publicado: (2022)

Neurolymphomatosis Appeared Following Primary Central Nervous System Lymphoma
por: Tanimizu, Masakuni, et al.
Publicado: (2017)

Acquired BTK mutations associated with resistance to noncovalent BTK inhibitors
por: Qi, Jialei, et al.
Publicado: (2023)

Primary central nervous system lymphoma
por: Gloghini, Annunziata, et al.
Publicado: (2015)

Primary central nervous system lymphoma
por: Löw, Sarah, et al.
Publicado: (2018)

Long-term Complete Remission of Decitabine-Primed Tandem CD19/CD22 CAR-T Therapy with PD-1 and BTK Inhibitors Maintenance in a Refractory Primary Central Nervous System Lymphoma Patient
por: Zou, Rui, et al.
Publicado: (2023)

Addition of BTK inhibitor orelabrutinib to rituximab improved anti-tumor effects in B cell lymphoma
por: Yu, Hui, et al.
Publicado: (2021)

Primary intercavernous lymphoma of the central nervous system
por: Dultra, Arthur Henrique de Aquino, et al.
Publicado: (2015)

Gastric Mucosa-Associated Lymphoid Tissue Lymphoma Followed by Primary Central Nervous System Lymphoma
por: Eom, Ki Seong, et al.
Publicado: (2012)

Molecular characteristics of immunocytes infiltration in primary central nervous system lymphoma
por: Zhang, Linyun, et al.
Publicado: (2022)

Relapsed Primary Central Nervous System Lymphoma: Current Advances
por: Tao, Kaiyan, et al.
Publicado: (2021)

Analysis of genomic alterations in primary central nervous system lymphoma
por: He, Xin, et al.
Publicado: (2023)

BTK Inhibitors and CAR T-Cell Therapy in Treating Mantle Cell Lymphoma—Finding a Dancing Partner
por: Munoz, Javier L., et al.
Publicado: (2022)

Differential impact of BTK active site inhibitors on the conformational state of full-length BTK
por: Joseph, Raji E, et al.
Publicado: (2020)

Molecular associations of response to the new-generation BTK inhibitor zanubrutinib in marginal zone lymphoma
por: Tatarczuch, Maciej, et al.
Publicado: (2023)

Are there primary intraocular lymphomas that do not develop into central nervous system lymphomas?
por: Matsuo, Toshihiko, et al.
Publicado: (2019)

Mutational analysis of primary central nervous system lymphoma
por: Bruno, Aurélie, et al.
Publicado: (2014)

Unusual relapse of primary central nervous system lymphoma
por: Igala, Marielle
Publicado: (2016)

Radiation Therapy for Primary Central Nervous System Lymphoma
por: Shibamoto, Yuta
Publicado: (2013)

Primary cardiac lymphoma with central nervous system relapse
por: van Rooijen, Cleo R., et al.
Publicado: (2017)

Advances in Pathobiology of Primary Central Nervous System Lymphoma
por: Yang, Xue-Liang, et al.
Publicado: (2017)

The Role of Rituximab in Primary Central Nervous System Lymphoma
por: Bromberg, Jacoline E. C., et al.
Publicado: (2020)

Primary peripheral T-cell central nervous system lymphoma
por: Bird, Cylaina E., et al.
Publicado: (2021)

Primary Central Nervous System Lymphoma With Systemic Recurrence
por: Pandravada, Sasirekha, et al.
Publicado: (2021)

Stereotactic Radiosurgery for Primary Central Nervous System Lymphoma
por: Wu, Susan Y, et al.
Publicado: (2023)

Clinical significance of polyglutamylation in primary central nervous system lymphoma
por: Shinojima, Naoki, et al.
Publicado: (2018)

A Fast and Clean BTK Inhibitor
por: Gabizon, Ronen, et al.
Publicado: (2020)

Targeting Solid Tumors With BTK Inhibitors
por: Uckun, Fatih M., et al.
Publicado: (2021)

Managing Waldenström’s macroglobulinemia with BTK inhibitors
por: Buske, Christian, et al.
Publicado: (2022)

Diagnosis and analysis of primary central nervous system lymphoma based on MRI segmentation algorithm
por: Lu, Guanping, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_32t5d31bsl5earfd5qkgcfd668